The original cardiovascular outcome trials for SGLT2 inhibitors in patients with type 2 diabetes seemed to be broadly beneficial based on subgroup analyses by age and sex.2, 28–30 Subsequent analyses have found that the efficacy and safety of dapagliflozin spans age and sex groups in patients with type 2 diabetes,31, 32 heart failure with preserved ejection fraction,33, 34 and heart failure with reduced ejection fraction.34–36. Here, SLC5A2 is linked to type 2 diabetes mellitus.